Who will be the new CEO?

Discussion in 'GlaxoSmithKline' started by anonymous, Dec 30, 2015 at 5:18 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Will it be an external or internal candidate?
     

  2. anonymous

    anonymous Guest

    very immature and vulgar............you will be warned soon !
     
  3. anonymous

    anonymous Guest

    You have misinterpreted the post and it's intent was not to be vulgar. All companies have a succession plan. Andrew is proving to be very prescient in terms of how he has set the company up for long-term success and employees and shareholders should be very pleased with him despite some pain from downsizing and realignment of therapeutic priorities/businesses. The oncology decision was bold and brilliant despite naysayers. Whether succession occurs a year from now or ten years there likely is a plan in place. Are they grooming a scientist/physician or business individual within GSK to eventually take over? Or will they select an outsider? That is the intention of this post, to create discussion not to take potshots at Andrew.
     
  4. anonymous

    anonymous Guest

    Even a trained monkey could make a right decision once in awhile... seems that's about all it takes.

    And yes, sick... and... Boing!
     
  5. anonymous

    anonymous Guest

    Your daddy was a trained monkey that threw darts.
     
  6. anonymous

    anonymous Guest

    Bozo the Clown would be a good candidate!
     
  7. anonymous

    anonymous Guest

    NO dammit.... entitlements!!!
     
  8. anonymous

    anonymous Guest

    This company does not need a change in leadership at this moment. That being said, AW was too young and inexperienced from day one. We are all suffering as a result of his pre-mature appointment. This company needs to acquire someone or some product! FAST!!!! That is the only thing that will save our future. Investors are calling for us to break up. If this were to be done, the individual divisions will be gobbled up by predatory companies such as Pfizer. AW, get off of your pompous British a$$ and make a move! Vaccines is a losing proposition. With no contracts and a volume based profit model...a losing strategy! You invested in emerging markets when you began. You bad mouthed the U.S. A decade later, and U.S. pharma still accounts for 40% of global sales. Emerging markets and their volatile geopolitical governments, societies, and religions have proven to be a drain on profits. It's time to acquire someone or something NOW!! Get rid of Inventive in the U.S.! They are not the solution and cost us millions. It's time AW! Make a move! And layoffs...you have done that three times in the last seven years. Time for a new strategy! Your people want to be proud again! Make it happen!
     
  9. anonymous

    anonymous Guest

    Triple boing!
     
  10. anonymous

    anonymous Guest

    Candidates are probably being considered and possibly interviewed. Witty will likely be out soon. In the end he's getting sacked just like he did to thousands of other GSK employees. Justice.
     
  11. anonymous

    anonymous Guest

    True bit he leave with millions and a knight. Not quite the same.
     
  12. anonymous

    anonymous Guest

    Witty and DC destroyed this company and every rep and investor knows it. Not sure why it took the Brits so long to see it. Either way he will leave a multi millionaire and we are the ones who got screwed
     
  13. anonymous

    anonymous Guest


    Sacked with a nice golden parachute and marathon medals from all over the world. Not quite.
     
  14. anonymous

    anonymous Guest

    Pretty much.

    Very sad
     
  15. anonymous

    anonymous Guest

    Socialist salesman, totally clueless
     
  16. anonymous

    anonymous Guest

    yes all of this is true. However whenever he is mentioned in the media going forward he will be forever linked to GSK. For example "Sir Andrew, the new Duke of Fiddle Faddle, was previously the CEO of GSK but stepped down due to a low volume, low margin strategy that went against all logic."
     
  17. anonymous

    anonymous Guest

    Yeah, because SAW's history of acquisitions has gone so well . . . Let's review - Stiefel, HGS, overpaying for NVS vaccine business so that you can crow about how "much you got" for your oncology business. BTW, what's the strategy in oncology? Become a biotech? Yeah, that'll work. Scientists are going to flock to GSK for that 6% dividend yield.

    FYI, there's no money to acquire anything. The company is staring down $20Bn in put options on Viiv and Cx that are coming due in the next couple of years, which is fortunate given this management's history of wasting the shareholders' money.
     
  18. anonymous

    anonymous Guest

    A good skipper goes down with his ship
     
  19. anonymous

    anonymous Guest

    Yea and an incompetent idiot skipper is the one who crashes and brings the ship down!